Mechanism

How it works

Upon mechanical overload or tissue damage, the IGF-1 gene is alternatively spliced to produce MGF, which contains a unique E-domain peptide sequence (the Ec peptide) not found in systemic IGF-1. MGF's Ec peptide activates quiescent muscle satellite cells, promoting their proliferation before they fuse with existing muscle fibers or form new ones. Separately, the IGF-1 portion of MGF can bind IGF-1 receptors and activate PI3K/Akt and MAPK/ERK signaling cascades to drive protein synthesis and suppress apoptosis.

Reported in research

Benefits

Stimulates activation and proliferation of muscle satellite cells, supporting muscle repair and growth
May accelerate recovery from exercise-induced muscle damage or injury
Potential neuroprotective effects observed in animal models of neuronal injury
Complements systemic IGF-1 activity by providing a localized anabolic and regenerative signal

Context, not a prescription

Dosing

Typical range: 200–500 mcg per injection site, 2–3 times per week (Subcutaneous, Intramuscular)
Cycle length: 4–6 weeks
Half-life: ~5–7 minutes (native peptide in serum; PEGylated forms extend to hours)

Safety

Side effects & contraindications

Possible side effects

Potential hypoglycemia due to IGF-1 receptor cross-activation
Injection site irritation, redness, or swelling
Possible water retention and soft-tissue edema
Theoretical risk of promoting growth in pre-existing neoplastic tissue
Headache and fatigue reported anecdotally

Contraindications

Active or history of hormone-sensitive cancers (breast, prostate, colorectal)
Diabetes or impaired glucose regulation without medical supervision
Pregnancy or breastfeeding
Pediatric or adolescent use (open growth plates)
Known hypersensitivity to IGF-1 pathway agonists

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Over a cycle, users report faster recovery between workouts, reduced muscle soreness duration, and gradual improvements in muscle fullness and size.

How it works

Imagine your muscle is a construction site that's been damaged. MGF is like the site foreman who calls in extra workers (satellite cells) who were sleeping in a break room. Once called, they get to work rebuilding and expanding the site.

After you inject MGF near a muscle, it binds to receptors on dormant muscle stem cells and tells them to wake up and multiply. It also taps into the same growth pathway as IGF-1, helping your body make more protein and prevent muscle cell death.

What to expect

Animal studies suggest satellite cell activation begins within 24–48 hours of administration, but noticeable physical changes in humans typically take several weeks of consistent use.

Week 1: Injection site responses may occur. Some users report improved workout recovery within a few days, though this is largely subjective at this stage.
Weeks 2-4: Satellite cell activation and proliferation may be underway. Reduced muscle soreness and improved recovery between sessions become more apparent.
Weeks 4-6: Cumulative muscle repair effects may translate to modest improvements in muscle fullness and size, particularly when combined with consistent resistance training.

Good to know

Always eat a carbohydrate-containing meal within 30 minutes of injection to prevent hypoglycemia
Start at the lower end of the dosing range (200 mcg) to assess tolerance before increasing

Staying safe

Low blood sugar (shakiness, dizziness, especially around workouts)
Injection site redness or swelling
Mild water retention or puffiness

Avoid if you have:

Anyone with a history of cancer
Diabetics without medical supervision
Pregnant or nursing women
Teenagers and young adults still growing

Overview

Histologically, increased satellite cell density, myonuclear accretion, and elevated MyoD and Myogenin expression are the primary early markers. Over 4–8 weeks, net muscle cross-sectional area increases, myofibrillar protein content rises, and connective tissue remodeling is enhanced. IGF-1R downstream signaling (p-Akt, p-S6K1 elevation) has been confirmed in rodent muscle biopsy data post-MGF administration.

How it works

Think of the IGF-1 gene as a master blueprint that can be read in multiple ways. Under mechanical stress, the cell's splicing machinery reads an alternate exon, producing a transcript that encodes the standard IGF-1 growth domain fused to a novel C-terminal tag (the Ec peptide). The Ec peptide functions as a localized emergency broadcast signal activating quiescent satellite cells specifically at the injury site, while the IGF-1 domain acts as a systemic regenerative amplifier once the Ec peptide is cleaved — two distinct tools from one genomic blueprint.

Following intramuscular or subcutaneous administration, the Ec peptide fragment is rapidly cleaved from the IGF-1 domain by local proteases. The Ec peptide (MGF peptide per se) acts locally via non-IGF-1R mechanisms to upregulate satellite cell mitotic activity. Concurrently, the liberated IGF-1 domain activates IGF-1R on myofibers and myoblasts, initiating canonical anabolic signaling. Systemic exposure is limited due to rapid proteolytic degradation. PEGylated-MGF has demonstrated prolonged half-life (~72+ hours in animal models) with sustained satellite cell activation and reduced injection frequency requirements.

Onset & timeline

Satellite cell entry into the cell cycle has been observed within 24–72 hours post-mechanical stimulus in murine models. With exogenous MGF administration, receptor engagement is near-immediate, but satellite cell proliferation peaks at approximately 48–96 hours. Clinically meaningful muscle remodeling in human analog studies would require weeks of consistent administration combined with mechanical overload.

Days 1-3: Rapid receptor binding and Ec peptide cleavage occur within minutes of injection. Satellite cell activation and cell-cycle entry initiated. Transient IGF-1R/Akt/mTOR activation measurable in myofibrillar tissue within 24 hours (based on rodent data).
Weeks 1-2: Satellite cell proliferation peaks. MyoD and Myf5 expression upregulated. Early myonuclear accretion begins in trabecular and fast-twitch fiber populations. Recovery metrics (creatine kinase normalization, perceived soreness) may improve.
Weeks 2-6: Cumulative anabolic effects through mTORC1/S6K1/4E-BP1 pathway sustained signaling. Net positive nitrogen balance, increased myofibrillar protein synthesis, and measurable hypertrophy in response to concurrent resistance training. Neuroprotective effects (in CNS injury models) peak in this window in animal research.

Getting the most from it

Monitor fasting glucose and IGF-1 serum levels at baseline and during cycle; adjust dose accordingly
Administer with or immediately following a carbohydrate-containing meal to mitigate hypoglycemic risk
Limit cycle length to 4–6 weeks with equal off-time to prevent receptor downregulation and theoretical mitogenic overcumulation
Consider PEGylated MGF if more consistent bioavailability is desired, using lower total doses due to extended half-life

Common side effects

Hypoglycemia secondary to IGF-1R activation — particularly risk in fasted states or periworkout administration without carbohydrate intake
Transient localized edema and cellular proliferation at injection site
Possible soft-tissue thickening with prolonged high-dose use

Mechanism of action

MGF (IGF-1Ec isoform) is generated by alternative splicing and frameshifting of the IGF-1 pre-mRNA in response to mechanical stimuli and tissue damage, regulated in part by local hypoxia and cytokine signaling. The unique 24-amino acid Ec peptide at the C-terminus of MGF acts independently of the IGF-1 receptor and is thought to interact with heparan sulfate proteoglycans on the satellite cell surface, triggering their activation and symmetric proliferation via p38 MAPK and Notch pathway modulation. The mature IGF-1 domain of MGF subsequently signals through the IGF-1R/IRS-1/PI3K/Akt/mTORC1 axis to upregulate protein synthesis and suppress FoxO-mediated atrogene expression, while the Ras/Raf/MEK/ERK cascade mediates additional mitogenic effects on myoblasts. Importantly, the native MGF Ec peptide is extremely labile in serum (half-life ~5–7 minutes), which is why PEGylated MGF variants have been developed to extend bioavailability.

Following intramuscular or subcutaneous administration, the Ec peptide fragment is rapidly cleaved from the IGF-1 domain by local proteases. The Ec peptide (MGF peptide per se) acts locally via non-IGF-1R mechanisms to upregulate satellite cell mitotic activity. Concurrently, the liberated IGF-1 domain activates IGF-1R on myofibers and myoblasts, initiating canonical anabolic signaling. Systemic exposure is limited due to rapid proteolytic degradation. PEGylated-MGF has demonstrated prolonged half-life (~72+ hours in animal models) with sustained satellite cell activation and reduced injection frequency requirements.

Pharmacodynamics

Satellite cell entry into the cell cycle has been observed within 24–72 hours post-mechanical stimulus in murine models. With exogenous MGF administration, receptor engagement is near-immediate, but satellite cell proliferation peaks at approximately 48–96 hours. Clinically meaningful muscle remodeling in human analog studies would require weeks of consistent administration combined with mechanical overload.

Histologically, increased satellite cell density, myonuclear accretion, and elevated MyoD and Myogenin expression are the primary early markers. Over 4–8 weeks, net muscle cross-sectional area increases, myofibrillar protein content rises, and connective tissue remodeling is enhanced. IGF-1R downstream signaling (p-Akt, p-S6K1 elevation) has been confirmed in rodent muscle biopsy data post-MGF administration.

Timeline

Days 1-3: Rapid receptor binding and Ec peptide cleavage occur within minutes of injection. Satellite cell activation and cell-cycle entry initiated. Transient IGF-1R/Akt/mTOR activation measurable in myofibrillar tissue within 24 hours (based on rodent data).
Weeks 1-2: Satellite cell proliferation peaks. MyoD and Myf5 expression upregulated. Early myonuclear accretion begins in trabecular and fast-twitch fiber populations. Recovery metrics (creatine kinase normalization, perceived soreness) may improve.
Weeks 2-6: Cumulative anabolic effects through mTORC1/S6K1/4E-BP1 pathway sustained signaling. Net positive nitrogen balance, increased myofibrillar protein synthesis, and measurable hypertrophy in response to concurrent resistance training. Neuroprotective effects (in CNS injury models) peak in this window in animal research.

Comparisons

MGF — effectiveness Moderate, safety Moderate, cost $$, Medium to use
IGF-1 LR3 — effectiveness High, safety Moderate, cost $$$, Medium to use
PEGylated MGF — effectiveness Moderate, safety Moderate, cost $$$, Medium to use

Adverse effects

Common:

Hypoglycemia secondary to IGF-1R activation — particularly risk in fasted states or periworkout administration without carbohydrate intake
Transient localized edema and cellular proliferation at injection site
Possible soft-tissue thickening with prolonged high-dose use

Rare:

Theoretical oncological risk: IGF-1R pathway upregulation has been implicated in promotion of several tumor types; incidence in research contexts unknown but warrants screening
Carpal tunnel-like symptoms from fluid retention (reported with IGF-1 class peptides generally)

Contraindications & risk mitigation

Contraindicated in:

Individuals with elevated IGF-1 serum levels or acromegalic features
Patients with diagnosed or suspected malignancy — particularly colorectal, breast, or prostate carcinoma given IGF-1R overexpression in these tissues
Individuals with type 1 or type 2 diabetes mellitus without endocrinological supervision
Those with Laron syndrome or other IGF-1 pathway disorders

Monitor fasting glucose and IGF-1 serum levels at baseline and during cycle; adjust dose accordingly
Administer with or immediately following a carbohydrate-containing meal to mitigate hypoglycemic risk
Limit cycle length to 4–6 weeks with equal off-time to prevent receptor downregulation and theoretical mitogenic overcumulation
Consider PEGylated MGF if more consistent bioavailability is desired, using lower total doses due to extended half-life

Qué hace

Over a cycle, users report faster recovery between workouts, reduced muscle soreness duration, and gradual improvements in muscle fullness and size.

Cómo funciona

Imagine your muscle is a construction site that's been damaged. MGF is like the site foreman who calls in extra workers (satellite cells) who were sleeping in a break room. Once called, they get to work rebuilding and expanding the site.

After you inject MGF near a muscle, it binds to receptors on dormant muscle stem cells and tells them to wake up and multiply. It also taps into the same growth pathway as IGF-1, helping your body make more protein and prevent muscle cell death.

Qué esperar

Animal studies suggest satellite cell activation begins within 24–48 hours of administration, but noticeable physical changes in humans typically take several weeks of consistent use.

Week 1: Injection site responses may occur. Some users report improved workout recovery within a few days, though this is largely subjective at this stage.
Weeks 2-4: Satellite cell activation and proliferation may be underway. Reduced muscle soreness and improved recovery between sessions become more apparent.
Weeks 4-6: Cumulative muscle repair effects may translate to modest improvements in muscle fullness and size, particularly when combined with consistent resistance training.

Bueno saber

Always eat a carbohydrate-containing meal within 30 minutes of injection to prevent hypoglycemia
Start at the lower end of the dosing range (200 mcg) to assess tolerance before increasing

Manteniéndose seguro

Low blood sugar (shakiness, dizziness, especially around workouts)
Injection site redness or swelling
Mild water retention or puffiness

Evitar si tienes:

Anyone with a history of cancer
Diabetics without medical supervision
Pregnant or nursing women
Teenagers and young adults still growing

Descripción general

Histologically, increased satellite cell density, myonuclear accretion, and elevated MyoD and Myogenin expression are the primary early markers. Over 4–8 weeks, net muscle cross-sectional area increases, myofibrillar protein content rises, and connective tissue remodeling is enhanced. IGF-1R downstream signaling (p-Akt, p-S6K1 elevation) has been confirmed in rodent muscle biopsy data post-MGF administration.

Cómo funciona

Think of the IGF-1 gene as a master blueprint that can be read in multiple ways. Under mechanical stress, the cell's splicing machinery reads an alternate exon, producing a transcript that encodes the standard IGF-1 growth domain fused to a novel C-terminal tag (the Ec peptide). The Ec peptide functions as a localized emergency broadcast signal activating quiescent satellite cells specifically at the injury site, while the IGF-1 domain acts as a systemic regenerative amplifier once the Ec peptide is cleaved — two distinct tools from one genomic blueprint.

Following intramuscular or subcutaneous administration, the Ec peptide fragment is rapidly cleaved from the IGF-1 domain by local proteases. The Ec peptide (MGF peptide per se) acts locally via non-IGF-1R mechanisms to upregulate satellite cell mitotic activity. Concurrently, the liberated IGF-1 domain activates IGF-1R on myofibers and myoblasts, initiating canonical anabolic signaling. Systemic exposure is limited due to rapid proteolytic degradation. PEGylated-MGF has demonstrated prolonged half-life (~72+ hours in animal models) with sustained satellite cell activation and reduced injection frequency requirements.

Inicio y cronología

Satellite cell entry into the cell cycle has been observed within 24–72 hours post-mechanical stimulus in murine models. With exogenous MGF administration, receptor engagement is near-immediate, but satellite cell proliferation peaks at approximately 48–96 hours. Clinically meaningful muscle remodeling in human analog studies would require weeks of consistent administration combined with mechanical overload.

Days 1-3: Rapid receptor binding and Ec peptide cleavage occur within minutes of injection. Satellite cell activation and cell-cycle entry initiated. Transient IGF-1R/Akt/mTOR activation measurable in myofibrillar tissue within 24 hours (based on rodent data).
Weeks 1-2: Satellite cell proliferation peaks. MyoD and Myf5 expression upregulated. Early myonuclear accretion begins in trabecular and fast-twitch fiber populations. Recovery metrics (creatine kinase normalization, perceived soreness) may improve.
Weeks 2-6: Cumulative anabolic effects through mTORC1/S6K1/4E-BP1 pathway sustained signaling. Net positive nitrogen balance, increased myofibrillar protein synthesis, and measurable hypertrophy in response to concurrent resistance training. Neuroprotective effects (in CNS injury models) peak in this window in animal research.

Cómo aprovecharlo al máximo

Monitor fasting glucose and IGF-1 serum levels at baseline and during cycle; adjust dose accordingly
Administer with or immediately following a carbohydrate-containing meal to mitigate hypoglycemic risk
Limit cycle length to 4–6 weeks with equal off-time to prevent receptor downregulation and theoretical mitogenic overcumulation
Consider PEGylated MGF if more consistent bioavailability is desired, using lower total doses due to extended half-life

Efectos secundarios comunes

Hypoglycemia secondary to IGF-1R activation — particularly risk in fasted states or periworkout administration without carbohydrate intake
Transient localized edema and cellular proliferation at injection site
Possible soft-tissue thickening with prolonged high-dose use

Mecanismo de acción

MGF (IGF-1Ec isoform) is generated by alternative splicing and frameshifting of the IGF-1 pre-mRNA in response to mechanical stimuli and tissue damage, regulated in part by local hypoxia and cytokine signaling. The unique 24-amino acid Ec peptide at the C-terminus of MGF acts independently of the IGF-1 receptor and is thought to interact with heparan sulfate proteoglycans on the satellite cell surface, triggering their activation and symmetric proliferation via p38 MAPK and Notch pathway modulation. The mature IGF-1 domain of MGF subsequently signals through the IGF-1R/IRS-1/PI3K/Akt/mTORC1 axis to upregulate protein synthesis and suppress FoxO-mediated atrogene expression, while the Ras/Raf/MEK/ERK cascade mediates additional mitogenic effects on myoblasts. Importantly, the native MGF Ec peptide is extremely labile in serum (half-life ~5–7 minutes), which is why PEGylated MGF variants have been developed to extend bioavailability.

Following intramuscular or subcutaneous administration, the Ec peptide fragment is rapidly cleaved from the IGF-1 domain by local proteases. The Ec peptide (MGF peptide per se) acts locally via non-IGF-1R mechanisms to upregulate satellite cell mitotic activity. Concurrently, the liberated IGF-1 domain activates IGF-1R on myofibers and myoblasts, initiating canonical anabolic signaling. Systemic exposure is limited due to rapid proteolytic degradation. PEGylated-MGF has demonstrated prolonged half-life (~72+ hours in animal models) with sustained satellite cell activation and reduced injection frequency requirements.

Farmacodinamia

Satellite cell entry into the cell cycle has been observed within 24–72 hours post-mechanical stimulus in murine models. With exogenous MGF administration, receptor engagement is near-immediate, but satellite cell proliferation peaks at approximately 48–96 hours. Clinically meaningful muscle remodeling in human analog studies would require weeks of consistent administration combined with mechanical overload.

Histologically, increased satellite cell density, myonuclear accretion, and elevated MyoD and Myogenin expression are the primary early markers. Over 4–8 weeks, net muscle cross-sectional area increases, myofibrillar protein content rises, and connective tissue remodeling is enhanced. IGF-1R downstream signaling (p-Akt, p-S6K1 elevation) has been confirmed in rodent muscle biopsy data post-MGF administration.

Cronología

Days 1-3: Rapid receptor binding and Ec peptide cleavage occur within minutes of injection. Satellite cell activation and cell-cycle entry initiated. Transient IGF-1R/Akt/mTOR activation measurable in myofibrillar tissue within 24 hours (based on rodent data).
Weeks 1-2: Satellite cell proliferation peaks. MyoD and Myf5 expression upregulated. Early myonuclear accretion begins in trabecular and fast-twitch fiber populations. Recovery metrics (creatine kinase normalization, perceived soreness) may improve.
Weeks 2-6: Cumulative anabolic effects through mTORC1/S6K1/4E-BP1 pathway sustained signaling. Net positive nitrogen balance, increased myofibrillar protein synthesis, and measurable hypertrophy in response to concurrent resistance training. Neuroprotective effects (in CNS injury models) peak in this window in animal research.

Comparaciones

MGF — efectividad Moderate, seguridad Moderate, costo $$, Medium de usar
IGF-1 LR3 — efectividad High, seguridad Moderate, costo $$$, Medium de usar
PEGylated MGF — efectividad Moderate, seguridad Moderate, costo $$$, Medium de usar

Efectos adversos

Comunes:

Hypoglycemia secondary to IGF-1R activation — particularly risk in fasted states or periworkout administration without carbohydrate intake
Transient localized edema and cellular proliferation at injection site
Possible soft-tissue thickening with prolonged high-dose use

Raros:

Theoretical oncological risk: IGF-1R pathway upregulation has been implicated in promotion of several tumor types; incidence in research contexts unknown but warrants screening
Carpal tunnel-like symptoms from fluid retention (reported with IGF-1 class peptides generally)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with elevated IGF-1 serum levels or acromegalic features
Patients with diagnosed or suspected malignancy — particularly colorectal, breast, or prostate carcinoma given IGF-1R overexpression in these tissues
Individuals with type 1 or type 2 diabetes mellitus without endocrinological supervision
Those with Laron syndrome or other IGF-1 pathway disorders

Monitor fasting glucose and IGF-1 serum levels at baseline and during cycle; adjust dose accordingly
Administer with or immediately following a carbohydrate-containing meal to mitigate hypoglycemic risk
Limit cycle length to 4–6 weeks with equal off-time to prevent receptor downregulation and theoretical mitogenic overcumulation
Consider PEGylated MGF if more consistent bioavailability is desired, using lower total doses due to extended half-life

Reference data

Specifications

Molecular formula: C121H200N42O39 (Ec peptide fragment; full MGF sequence varies by construct)
Molecular weight: ~2867 Da (Ec peptide); full-length MGF ~8–10 kDa
Half-life: ~5–7 minutes (native peptide in serum; PEGylated forms extend to hours)
Route: Subcutaneous, Intramuscular
Cycle length: 4–6 weeks
Storage: Store lyophilized powder at -20°C (freezer). After reconstitution with bacteriostatic water, store at 2–8°C (refrigerator) and use within 2–4 weeks. Avoid repeated freeze-thaw cycles. Keep away from light and heat.
Legal status: Not approved by the FDA or EMA for human therapeutic use. Classified as a research chemical in most jurisdictions. Prohibited in competitive sport by WADA under the S2 (Peptide Hormones, Growth Factors) category.

FAQ

Common questions

What is the pharmacokinetic rationale for using PEGylated MGF over native MGF?

Native MGF Ec peptide has a serum half-life of approximately 5–7 minutes due to rapid endopeptidase activity. PEGylation (polyethylene glycol conjugation) sterically shields proteolytic cleavage sites, extending the half-life to 72+ hours in murine models (Yang et al., 2009, Journal of Cachexia, Sarcopenia and Muscle). This allows for less frequent dosing and more sustained satellite cell activation without the need for immediate post-workout injection timing.

How does MGF differ mechanistically from IGF-1 LR3?

IGF-1 LR3 is a synthetic analog of systemic IGF-1 with an Arg-3 substitution and extended N-terminus that reduces IGF binding protein affinity, prolonging its half-life (~20 hours) and systemic IGF-1R activation. MGF, by contrast, exerts its primary muscle-specific effect through the Ec peptide acting on satellite cells via non-IGF-1R mechanisms before being cleaved to release the IGF-1 domain. MGF is considered to provide a more localized, satellite-cell-centric anabolic stimulus, while IGF-1 LR3 has broader systemic anabolic and anti-catabolic effects. Stacking both may provide complementary mechanisms but substantially increases IGF-1 pathway load and associated risks.

Is there any human clinical trial data for MGF?

As of the current knowledge cutoff, there are no published Phase I/II human clinical trials specifically for exogenous MGF administration. Evidence is derived primarily from in vitro myoblast studies and rodent in vivo models. Goldspink and colleagues (University College London) have been the primary researchers describing endogenous MGF physiology. Human application remains extrapolative from animal data, and all use outside supervised research settings carries unknown risk.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for Mechano Growth Factor (MGF) is rated as Animal data. Research is based primarily on animal models.

1. Mechano Growth Factor: a tissue-specific anabolic and repair factor (2007) — Annals of the New York Academy of Sciences; Goldspink G, doi: 10.1196/annals.1392.011
2. Alternatively spliced mechano growth factor (MGF) propeptide changes localization according to stress to regulate the activity of the IGF-1 receptor in skeletal muscle (2011) — Journal of Cell Science; Dluzniewska J et al.
3. PEGylation of mechano growth factor affects its nuclear import in myoblasts (2009) — Journal of Cachexia, Sarcopenia and Muscle; Yang SY et al.
4. Muscle fiber type-specific satellite cell activation and proliferation in response to mechanical overload (2005) — Journal of Applied Physiology

Explore

Often discussed alongside

IGF-1 LR3 · growth BPC-157 · healing TB-500 · healing GHRP-6 · growth CJC-1295 · growth